Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat

Synapse

Volumn 55, Issue 1, 2005, Pages 26-36

  Olds, M E ^a   Jacques, D B ^b   Kopyov, O ^b  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^b NEUROSCIENCES INSTITUTE   (United States)

Author keywords

Dopamine; Quinolinic acid; Rotation; Striatum

Indexed keywords

AMPHETAMINE; OXIDOPAMINE; QUINOLINIC ACID;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX ATROPHY; BRAIN TISSUE; COMPETITIVE BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DEAFFERENTATION; DRUG DETERMINATION; HUNTINGTON CHOREA; HYPOKINESIA; IMMUNOREACTIVITY; MALE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAT; SHAM FEEDING; SPECIES COMPARISON; STEREOTYPY; SUBSTANTIA NIGRA;

ADRENERGIC AGENTS; AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FUNCTIONAL LATERALITY; HUNTINGTON DISEASE; LOCOMOTION; MALE; NEUROTOXINS; OXIDOPAMINE; PARKINSON DISEASE; QUINOLINIC ACID; RATS; ROTATION; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA;

EID: 9444264293     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20082     Document Type: Article

References (36)

1. Albin RL, Young AB, Penny JB. 1989. The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366-375.
2. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. 1986. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321:168-171.
3. Bjorklund A, Stenevi U. 1979. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 177:555-560.
4. Cepeda C, Hurst RS, Altemus KL, Flores-Hernandez J, Calvert CR, Jokel ES, Grandy DK, Low MJ, Rubinstein M, Ariano MA, Levine MS. 2001. Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J Neurophysiol 85(2):659-670.
5. Chesselet MF, Delfs JM. 1996. Basal ganglia and movement disorders: an update. TINS 19:416-422.
6. Dawson TM, Dawson VL, Gage FH, Fisher LJ, Hunt MA, Wamsley JK. 1991. Functional recovery of supersensitive DA receptors after intrastriatal grafts of fetal substantia nigra. Exp Neurol 111:282-292.
7. DeLong MR. 1990. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281-285.
8. DiFiglia M. 1990. Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci 13:286-289.
9. Dunnett SB, Bjorklund A, Schmidt RH, Stenevi U, Iversen SD. 1983. Intracerebral grafting of neuronal cell suspensions. IV. Behavioral recovery in rats with unilateral 6-OHDA lesions following implantation of nigral cell suspensions in different brain sites. Acta Physiol Scand Suppl 522:29-37.
10. Freed WJ, Perlow MJ, Karoum F, Serger A, Olson L, Hoffer BJ. 1980. Restoration of dopaminergic function by grafting of fetal substantia nigra to the caudate nucleus: long-term behavioral, biochemical and histochemical studies. Ann Neurol 8:510-519.
11. Garside S, Furtado JCS, Mazurek MF. 1996. Dopamine-glutamate interactions in the striatum: behaviourally relevant modification of excitotoxicity by dopamine-receptor-mediated mechanisms. Neuroscience 75:1065-1074.
12. Graybiel AM. 1990. Neurotranamitters and neuromodulators in the basal ganglia. Trends Neurosci 13:244-204.
13. Greenamyre JT, Obrien CF. 1991. NMDA antagonists in the treatment of Parkinson's disease. Arch Neurol 48:977-981.
14. Hauber W, Schmidt WJ. 1994. Differential effects of lesions of the dorsomedial and dorsolateral caudate-putamen on reaction time performance in rats. Behav Brain Res 60:211-215.
15. Hornykiewiecz O. 1982. Brain transmitter changes in Parkinson's disease. In: Marsden CD, Fahn S, editors. Movement disorders, vol. 2. London: Butterworth Scientific, p 41-58.
16. Iversen SD. 1977. Brain dopamine systems and behavior. In: Iversen LL, Iversen SD, Snyder SH, editors. Drugs transmitters and behaviour handbook of psychopharmacology, vol. 8. New York: Plenum Press, p 333-384.
17. Joel D, Weiner I. 2000. The connections of the dopamiuergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 96:451-474.
18. Joel D, Ayalon L, Tarrasch R, Veenman L, Feldon J, Weiner I. 1998. Electrolytic lesion of globus pallidus ameliorates the behavioral and neurodegenerative effects of quinolinic acid lesion of the striatum: a potential novel treatment in a rat model of Huntington's disease. Brain Res 787:143-148.
19. Lewis SJG, Caldwell MA, Barker RA. 2003. Modern therapeutic approaches in Parkinson's disease. Exp Rev Mol Med 5:1-20.
20. Martin JB. 1986. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321:168-171.
21. Olds ME, Jacques DB, Kopyov O. 1999. Subthalamic responses to amphetamine and apomorphine in the behaving rat with a unilateral 6-OHDA lesion in the substantia nigra. Synapse 34:228-240.
22. Olds ME, Jacques DB, Kopyov O. 2003. Behavioral and subthalamic effects of combining a fetal ventral mesencephalic transplant in striatum with an electrolytic lesion of the entopeduncular nucleus in the rat with a unilateral 6-OHDA lesion of substantia nigra. Synapse 48:90-99.
23. Paxinos G, Watson C. 1983. The rat brain in stereotaxic coordinates. New York: Academic Press.
24. Pycock CJ. 1980. Turning behavior in animals. Neuroscience 5:461-514.
25. Reuter I, Grigorian G, French S, Hodges H, Chaudhuri KR. 1999. Striatal excitotoxic lesions in rats as a model for Huntington's disease: behavioural and histological comparisons of ibotenic and quinolinic acid. 7th International Symposium on Neural Transplantation (INT-7), 26th-30th July, Odense, Denmark.
26. Roberts IC, DiFiglia M. 1989. Short and long-term survival of large neurons in the excitotoxic lesioned rat caudate nucleus: a light and electron microscopic study. Synapse 3:363-371.
27. Scarr E, Wingerchuk DM, Juorio AV, Paterson IA. 1994. The effects of monoamine oxidase B inhibition on dopamine metabolism in rats with nigro-striatal lesions. Neurochem Res 19:153-159.
28. Schmidt WJ. 1998. Dopamine-glutamate interactions in the basal ganglia. Amino Acids 14:5-10.
29. Schwarcz R, Whetsell WO, Mangano RM. 1983. Quinolinic acid, an endogenous metabolite, can produce axon-sparing lesions in rat brain. Science 219:316-318.
30. Stone TW. 1993. Neuropharmacology of quinolinic acid and kynurenic acids. Pharmacol Rev 45:309-379.
31. Stone TW. 2001. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog Neurobiol 64:185-218.
32. Ungerstedt U. 1971a. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behavior. Acta Physiol Scand Suppl 367:49-68.
33. Ungerstedt U. 1971b. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:69-93.
34. Verhagen L, Metman P, Del Dotto P, Blanchet P, Munckhof VD, Chase TN. 1998. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids 14:75-82.
35. Weihmuller FB, Ulas J, Nguyen L, Cotman CW, Marshall JF. 1992. Elevated NMDA receptors in Parkinson striatum. Neuroreport 3:977-980.
36. Whetsell WO. 2002. The mammalian striatum and neurotoxic injury. Brain Pathol 12:482-487.